← Leaderboards
Adam L Halberstadt
University Of Pittsburgh At Pittsburgh
$2,627,327
Attributed
$3,504,424
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $746.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,504,424 · 6
By mechanism
R01$2,364,760 · 2
K01$465,818 · 1
R21$434,500 · 1
F32$156,942 · 1
F31$82,404 · 1
Top collaborators
- John D Mccorvy2 shared
- Kevin Sean Murnane2 shared
- Jared William Young2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Andrew F. Stewart$27,613,128
Others in their field
Top investigators on “Rodent”
- David Heimbrook · Leidos Biomedical Research, Inc.$173,257,325
- Dafna Bar-Sagi · State University New York Stony Brook$58,193,722
- Polly Chang · Sri International$53,674,299
- Ed Lein · Allen Institute$41,433,793
- Neil Scott Lipman · Sloan-Kettering Inst Can Research$39,869,247
- Hongkui Zeng · Allen Institute$37,381,292
Research focus
RodentHallucinogensBehaviorMediatingBehavioralReceptorBaseHtr2a GeneSerotoninDesignBrainResponseSerotonin ReceptorPropertyPharmaceutical PreparationsAttenuatedClinical EfficacyLinkNeuronsDrug Effect DisorderDrug Of AbuseNeurochemistryPharmacologyDesigner Drugs
Grant awards (16)
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder$480,492
R01 · FY2025 · DA
Determining the efficacy of psychedelic agents reversing depression-relevant amotivated behaviors with concomittant EEG biomarkers.$197,500
R21 · FY2025 · MH
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder$509,279
R01 · FY2024 · DA
Determining the efficacy of psychedelic agents reversing depression-relevant amotivated behaviors with concomittant EEG biomarkers.$237,000
R21 · FY2024 · MH
The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive Drugs$348,750
R01 · FY2020 · DA · contact PI
The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive Drugs$348,750
R01 · FY2019 · DA · contact PI
The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive Drugs$338,268
R01 · FY2018 · DA · contact PI
The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive Drugs$339,221
R01 · FY2017 · DA · contact PI
Role of the prefrontal cortex in serotonergic modulation of interval timing$154,823
K01 · FY2016 · MH · contact PI
Role of the prefrontal cortex in serotonergic modulation of interval timing$155,273
K01 · FY2015 · MH · contact PI
Role of the prefrontal cortex in serotonergic modulation of interval timing$155,722
K01 · FY2014 · MH · contact PI
Mechanisms of hallucinogen effects on exploratory behavior in rats and mice$54,734
F32 · FY2011 · DA · contact PI
Mechanisms of hallucinogen effects on exploratory behavior in rats and mice$52,154
F32 · FY2010 · DA · contact PI
Mechanisms of hallucinogen effects on exploratory behavior in rats and mice$50,054
F32 · FY2009 · DA · contact PI
Raphe Nuclei Projections to Vestibular Nuclei$41,202
F31 · FY2005 · DC
Raphe Nuclei Projections to Vestibular Nuclei$41,202
F31 · FY2004 · DC